tradingkey.logo
tradingkey.logo

Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Prostate Cancer

ReutersMar 16, 2026 11:40 AM

- Monte Rosa Therapeutics Inc GLUE.O:

  • MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF MRT-2359 WITH APALUTAMIDE IN Q3 2026

  • MONTE ROSA THERAPEUTICS INC - ENTERS SUPPLY AGREEMENT WITH JOHNSON & JOHNSON FOR PHASE 2 MCRPC STUDY STARTING Q3 2026

  • MONTE ROSA THERAPEUTICS INC - TO CONDUCT AND SPONSOR TRIAL; JOHNSON & JOHNSON TO SUPPLY ERLEADA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI